SlideShare a Scribd company logo
1 of 1
TEMPLATE DESIGN © 2008
www.PosterPresentations.com
On average, participants were between
“Confident” and “Very Confident” in their
treatment choice.
Participants were asked how confident they were with
their treatment choice on a 6-point Likert scale (Not at all
confident, Only slightly confident, Moderately confident,
Confident, Very confident, Absolutely confident). After
performing a Chi-squared test, Figure 2.1 shows no
significant difference (p=.29) between the levels of
disclosure when patients are asked how confident they
are in their treatment choice. Basically, all the patients felt
that they had made the correct decision based on the
information they received. This indicates that participants
were not confused by the disclosure information that they
were confronted with despite the medical jargon and
increased information that increased disclosure entailed.
Effects of Conflict of Interest on Patient Action and Attitude
Roy Spece, Andrea-Gale Okoro, Ryan Keim
1 University of Arizona, James E. Rogers College of Law, 2 University of Arizona, Honors College
Introduction
Several studies show that physician financial conflicts of interest
(“COI”) significantly increase the likelihood that conflicted physicians will
order diagnostic and treatment modalities, including invasive procedures
such as surgery. Many court decisions and regulations mandate
disclosure of any and all information that a reasonable patient would
consider material to his medical choices. Disclosure is often suggested
as a remedy in the medical and other contexts, but current literature
leaves uncertain disclosure’s effects on patient attitudes and action.
Some studies suggest that disclosure does not change patients’
acceptance of physician recommendations, while others claim
disclosure can have perverse effects such as giving patients a false
sense of security. Central to court or legislative decisions whether
disclosure of COI must or should be made to patients is whether
disclosure does affect patients’ decisions. If it does, then that is strong
evidence that patients in fact consider COI to be material information.
This study investigates how patients react when confronted with
information about their physicians’ COI’s in the form of ownership
interests in facilities where recommended procedures will be done.
Using participants from all over the country to experience our vignettes
involving physician recommendations and patient choices between drug
therapy or an invasive procedure for coronary artery disease, we were
able to evaluate, through survey questions and scales, exactly how
patients are affected by disclosure. Especially important is our finding
that disclosure does significantly increase the probability that patients’
will reject their physicians’ recommendations.
.
Methods
Logistic Regression Model of Treatment Choice
Ordinal Regression Model of Confidence in Physicians
On average, participants
were between
“Confident” and “Very
Confident” in their
treatment choices. .
Likelihood of Seeking a Second Opinion
Discussion
Acknowledgments
Though there was a significant difference in likelihood of
seeking a second opinion between the levels of disclosure,
patients were generally leaning towards a 2nd opinion. When
asked to rank “likeliness” of seeking a second opinion on a 6pt, fully
anchored Likert scale (1=Very Unlikely, 6= Very Likely), participants were
generally between “Somewhat Likely” and “Very Likely” (88%). Thirty-
seven percent of participants who received Full Disclosure were “Very
Likely” to seek a second opinion, versus 27% of those who received No
Disclosure.. (X2 (10)= 25.793, p = 0.004)
Federalandstatestatutes,regulations,andcommonlawopinionsgoverninformation
transferfromphysicianstopatients. Thefindingsheremightinformwhetherandhowthese
legalmandatesshouldbealteredorbroadened,particularlyinthecurrentlyuncertaincontext
ofdisclosureoffinancialconflictsofinterest.Therearethreegeneralrulesadoptedincases
andregulationsconcerningdisclosurerequiredunderthedoctrineofinformedconsent:one
mustdisclosethatwhichwouldbethoughtreasonablebyphysiciansgenerally,onemust
disclosewhatareasonablepatientwouldconsidermaterialtohisdecisionmaking,andwhat
theparticularpatientwouldconsidermaterialtohisdecisionmaking.Applicationofthebasic
doctrinallawinthosejurisdictionthatrequiredisclosureofwhatareasonablepatientwould
considermaterialdepends,inwholeorpart, onanempiricalquestionastowhatreasonable
personswouldconsidermaterialinspecificscenarios. Thelatterquestiondepends
substantiallyonwhatinfactaffectspatients’actualdecisions. Thispaperexaminesthelatter
questionby,inturn,askingwhetherpatients’decisionsareaffectedbydisclosure—atdifferent
levelsofdetail—ofphysicians’financialconflictsofinterestintheformofownershipinterestsin
hospitalswhererecommendedprocedureswouldtakeplace.Ourfindingsintheclinical
practicecontextarethatthefactofdisclosure,butnotanincreasedlevelofdisclosure,does
significantlyaffectpatients’propensitytorejectfinanciallyconflictedphysicians’
recommendations.Therefore,itlogicallyfollowsthatsuchconflictsofinterestareinfact
materialtopatientdecisionmaking. Onecanarguethatsuchproofshowsthatlegalbodies
shouldadoptthepatient-orienteddisclosurerule,atleastinthecontextoffinancialconflictsof
interest.Othershaveobjectedthatsuchdisclosuresmightconfusepatientsorgivethema
falsesenseofsecurityabouttheirdoctors’fealty. Anotherobjectionisthatsuchdisclosures
areunwarrantedbecausetheywillnotaffectpatients’decisions. Thefindingsherecontradict
alltheseargumentsagainstdisclosure. Ourfindingsarenotonlythatdisclosureincreases
patients’propensitytorejectphysicianadvice,butalsothat,withdisclosure,patientsare
confidentintheirdecisions,aremorewaryoftheirphysicians,andmorelikelytoseeksecond
opinions.
Subjects were given one of three different vignettes either
as a high risk patient (someone who has had a heart
attack previously and therefore at higher risk of having
another) or a low risk patient (someone who has not
previously had a heart attack). The three vignettes varied
by disclosure, ranging from “No Disclosure” to “
Disclosure” to “Enhanced Disclosure”, but all ended with
the same two doctor recommendations and patient
choices. After reading their vignettes, participants were
asked a series of questions in order to measure changes
in their medical choice, opinion of the doctor’s fealty, and
understanding of the situation.
Participants
777 subjects, recruited online via Amazon Mechanical
Turk with a $0.75 incentive, consented to participate; 34
did not complete the entire experiment and 64 were
excluded for not complete the survey in a timely manner,
bringing the final sample to 691 subjects. The sample
was predominantly white (78%) and male (61%), with
some college (35%) or a Bachelor’s degree (35%), and
an average age of 28 years.
Figure 1| Note: Model χ2 (2) = 11.4, p = .003.
Full disclosure
basically inverted
treatment choice
against the doctor’s
recommendation.
Shown in both Figure 1
and Figure 1.4,
increased disclosure
significantly increased
the likelihood that
patients would ignore
the doctor’s
recommendation and opt
for drug therapy.
Figure 1.4 This figure shows the percent
change, or uptake, in respondents who
chose the recommended PCI treatment
across the levels of disclosure and risk
Figure 6. 2x3 Factorial
Design for the
experiment show all
possible options for
participants, assigned
randomly.
Figure 3.1 This figure shows
how respondents differed in
Q27, stratified by risk and
separated by disclosure level.
Figure 3| Note: Model χ2 (10) = 98.102, p < .001.
Understanding the Treatment Choice
Despite increased information with increased
disclosure, participants understood their choices
across all levels.
A simple visual and statistical comparison of responses to the
statement "I fully understand the treatment choices presented to
me by the cardiologist“ demonstrates that despite conclusions of
past literature, disclosing COI does not overwhelm patients or
impair their ability to make decisions. In a fully anchored 6pt-
Likert scale (Strongly Disagree – Strongly Agree), participants in
all levels generally fell into the “Agree” category (47%).
Figure 5.1 Given a fully
anchored 6pt-Likert scale
(1= Strongly Disagree and
6= Strongly Agree) this figure
illustrates how respondents,
separated by risk and
disclosure, felt they
understood the information
given to them.
X2 (10)= 5.716,
p = 0.839
Confidence in Treatment Choice
Figure 2.1 This figure
shows the average
confidence levels of
respondents, in their
treatment choice, in terms
of risk level and
disclosure level.
Thanks to Dr. Charles Okoro for medical accuracy review. Thanks to Christopher
Robertson and David Yokum for research guidance. Thanks to the James E. Roger Law
School and University of Arizona Honors college for financial and educational support.
Future Directions
Given that our findings contradict those in a few other somewhat
analogous investigations, we invite others to attempt to duplicate
our findings. There is also need for studies that investigate the
effects of other financial conflicts of interest such as fee-for-
service payment, receipt of monies or other perks from
pharmaceutical companies, and HMO financial incentives (be
they carrot or stick).
*
Figure 4.1 Subjects’
likelihood of seeking a
second opinion after
receiving the
information on their
treatment options from
the doctor, separated
by levels of disclosure
and risk. *
Which course of treatment do you want to select?”)
Q21
Disclosure Drug Therapy PCI Treatment Row Total
----------------------- ----------- ----------- -----------
Full Count 146 91 237
Row % 61.60% 38.40% 34.30%
Column % 38.42% 29.26%
----------------------- ----------- ----------- -----------
None Count 110 127 237
Row % 46.41% 53.59% 34.30%
Column % 28.95% 40.84%
----------------------- ----------- ----------- -----------
Partial Count 124 93 217
Row % 57.14% 42.86% 31.40%
Column % 32.63% 29.90%
----------------------- ----------- ----------- -----------
Column Total 380 311 691
Column % 54.99% 45.01%
========== Table: Disclosure by Q27 ==========
Q27 "The cardiologist had only my interests in mind in making his recommendation."
Disclosure Strongly Disagree Disagree Somewhat Disagree Somewhat Agree Agree Strongly Agree Row Total
----------------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
Full Count 13 40 56 78 38 12 237
Row % 5.49% 16.88% 23.63% 32.91% 16.03% 5.06% 34.30%
Column % 41.94% 43.96% 44.09% 37.50% 21.35% 21.43%
----------------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
None Count 1 8 28 72 94 34 237
Row % 0.42% 3.38% 11.81% 30.38% 39.66% 14.35% 34.30%
Column % 3.23% 8.79% 22.05% 34.62% 52.81% 60.71%
----------------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
Partial Count 17 43 43 58 46 10 217
Row % 7.83% 19.82% 19.82% 26.73% 21.20% 4.61% 31.40%
Column % 54.84% 47.25% 33.86% 27.89% 25.84% 17.86%
----------------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
Column Total 31 91 127 208 178 56 691
Column % 4.49% 13.17% 18.38% 30.10% 25.76% 8.10%
No Disclosure Full Disclosure Partial Disclosure
High Risk Previous MI
No Disclosure
Previous MI
Disclosure
Explanation of Disclosure
Previous MI
Disclosure
Low Risk No MI
No Disclosure
No MI
Disclosure
Explanation of Disclosure
No MI
Disclosure
Understandingofchoices

More Related Content

What's hot

23204998
2320499823204998
23204998radgirl
 
Outcome Rating Scale (ORS)
Outcome Rating Scale (ORS)Outcome Rating Scale (ORS)
Outcome Rating Scale (ORS)Barry Duncan
 
ReeseTolandSloneNorsworthy2010
ReeseTolandSloneNorsworthy2010ReeseTolandSloneNorsworthy2010
ReeseTolandSloneNorsworthy2010Barry Duncan
 
GettingBetterAtWhatWeDo
GettingBetterAtWhatWeDoGettingBetterAtWhatWeDo
GettingBetterAtWhatWeDoBarry Duncan
 
The Partners for Change Outcome Management System: Duncan & Reese, 2015
The Partners for Change Outcome Management System: Duncan & Reese, 2015The Partners for Change Outcome Management System: Duncan & Reese, 2015
The Partners for Change Outcome Management System: Duncan & Reese, 2015Barry Duncan
 
Child Outcome Rating Scale (CORS)
Child Outcome Rating Scale (CORS)Child Outcome Rating Scale (CORS)
Child Outcome Rating Scale (CORS)Barry Duncan
 
Therapeutic Misconception in Oncologic Research
Therapeutic Misconception in Oncologic ResearchTherapeutic Misconception in Oncologic Research
Therapeutic Misconception in Oncologic Researchbodekerk
 
ApplyingOutcomeResearch
ApplyingOutcomeResearchApplyingOutcomeResearch
ApplyingOutcomeResearchBarry Duncan
 
Psychometric Properties of the ORS and SRS
Psychometric Properties of the ORS and SRSPsychometric Properties of the ORS and SRS
Psychometric Properties of the ORS and SRSScott Miller
 
Statistics basics for oncologist kiran
Statistics basics for oncologist kiranStatistics basics for oncologist kiran
Statistics basics for oncologist kiranKiran Ramakrishna
 
Beyond measures and monitoring
Beyond measures and monitoringBeyond measures and monitoring
Beyond measures and monitoringScott Miller
 
Article from the National Psychologist about Scott Miller's speech at Evoluti...
Article from the National Psychologist about Scott Miller's speech at Evoluti...Article from the National Psychologist about Scott Miller's speech at Evoluti...
Article from the National Psychologist about Scott Miller's speech at Evoluti...Scott Miller
 
Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Cochrane.Collaboration
 
Medication Adherence and its Relationship to the Therapeutic Alliance
Medication Adherence and its Relationship to the Therapeutic AllianceMedication Adherence and its Relationship to the Therapeutic Alliance
Medication Adherence and its Relationship to the Therapeutic AllianceScott Miller
 
Does publication bias inflate the apparent efficacy of psychological treatmen...
Does publication bias inflate the apparent efficacy of psychological treatmen...Does publication bias inflate the apparent efficacy of psychological treatmen...
Does publication bias inflate the apparent efficacy of psychological treatmen...Scott Miller
 
ReeseUsherBowmanetetal
ReeseUsherBowmanetetalReeseUsherBowmanetetal
ReeseUsherBowmanetetalBarry Duncan
 

What's hot (20)

23204998
2320499823204998
23204998
 
Outcome Rating Scale (ORS)
Outcome Rating Scale (ORS)Outcome Rating Scale (ORS)
Outcome Rating Scale (ORS)
 
ORS Replication
ORS ReplicationORS Replication
ORS Replication
 
ReeseTolandSloneNorsworthy2010
ReeseTolandSloneNorsworthy2010ReeseTolandSloneNorsworthy2010
ReeseTolandSloneNorsworthy2010
 
GettingBetterAtWhatWeDo
GettingBetterAtWhatWeDoGettingBetterAtWhatWeDo
GettingBetterAtWhatWeDo
 
Ck article ijpp
Ck article ijppCk article ijpp
Ck article ijpp
 
The Partners for Change Outcome Management System: Duncan & Reese, 2015
The Partners for Change Outcome Management System: Duncan & Reese, 2015The Partners for Change Outcome Management System: Duncan & Reese, 2015
The Partners for Change Outcome Management System: Duncan & Reese, 2015
 
Child Outcome Rating Scale (CORS)
Child Outcome Rating Scale (CORS)Child Outcome Rating Scale (CORS)
Child Outcome Rating Scale (CORS)
 
Therapeutic Misconception in Oncologic Research
Therapeutic Misconception in Oncologic ResearchTherapeutic Misconception in Oncologic Research
Therapeutic Misconception in Oncologic Research
 
ApplyingOutcomeResearch
ApplyingOutcomeResearchApplyingOutcomeResearch
ApplyingOutcomeResearch
 
Psychometric Properties of the ORS and SRS
Psychometric Properties of the ORS and SRSPsychometric Properties of the ORS and SRS
Psychometric Properties of the ORS and SRS
 
JBKjerhre
JBKjerhreJBKjerhre
JBKjerhre
 
Statistics basics for oncologist kiran
Statistics basics for oncologist kiranStatistics basics for oncologist kiran
Statistics basics for oncologist kiran
 
Beyond measures and monitoring
Beyond measures and monitoringBeyond measures and monitoring
Beyond measures and monitoring
 
Article from the National Psychologist about Scott Miller's speech at Evoluti...
Article from the National Psychologist about Scott Miller's speech at Evoluti...Article from the National Psychologist about Scott Miller's speech at Evoluti...
Article from the National Psychologist about Scott Miller's speech at Evoluti...
 
Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?
 
Medication Adherence and its Relationship to the Therapeutic Alliance
Medication Adherence and its Relationship to the Therapeutic AllianceMedication Adherence and its Relationship to the Therapeutic Alliance
Medication Adherence and its Relationship to the Therapeutic Alliance
 
Does publication bias inflate the apparent efficacy of psychological treatmen...
Does publication bias inflate the apparent efficacy of psychological treatmen...Does publication bias inflate the apparent efficacy of psychological treatmen...
Does publication bias inflate the apparent efficacy of psychological treatmen...
 
ReeseUsherBowmanetetal
ReeseUsherBowmanetetalReeseUsherBowmanetetal
ReeseUsherBowmanetetal
 
Ebd jc part 5
Ebd jc part 5Ebd jc part 5
Ebd jc part 5
 

Similar to Patient Treatment Choices and Confidence with Physician Conflict of Interest Disclosure

An Internet questionnaire to identify Drug seeking behavior in a patient in t...
An Internet questionnaire to identify Drug seeking behavior in a patient in t...An Internet questionnaire to identify Drug seeking behavior in a patient in t...
An Internet questionnaire to identify Drug seeking behavior in a patient in t...Nelson Hendler
 
Pain Validity Test to detect drug seeking behavior
Pain Validity Test to detect drug seeking behaviorPain Validity Test to detect drug seeking behavior
Pain Validity Test to detect drug seeking behaviorNelson Hendler
 
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...Nelson Hendler
 
Clearing the Error: Patient Participation in Reducing Diagnostic Error
Clearing the Error: Patient Participation in Reducing Diagnostic ErrorClearing the Error: Patient Participation in Reducing Diagnostic Error
Clearing the Error: Patient Participation in Reducing Diagnostic ErrorJefferson Center
 
Pati ent Sati sfacti on in Electi ve Major Surgery for Benign
Pati ent Sati sfacti on in Electi ve Major Surgery for BenignPati ent Sati sfacti on in Electi ve Major Surgery for Benign
Pati ent Sati sfacti on in Electi ve Major Surgery for Benignarbin joshi
 
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxRunning head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxtodd271
 
MedicalResearch.com: Medical Research Exclusive Interviews March 24 2015
MedicalResearch.com:  Medical Research Exclusive Interviews March 24 2015MedicalResearch.com:  Medical Research Exclusive Interviews March 24 2015
MedicalResearch.com: Medical Research Exclusive Interviews March 24 2015Marie Benz MD FAAD
 
Predicting Patient Interest and Participation in Clinical Trials
Predicting Patient Interest and Participation in Clinical TrialsPredicting Patient Interest and Participation in Clinical Trials
Predicting Patient Interest and Participation in Clinical TrialsNassim Azzi, MBA
 
Predicting Patient Adherence: Why and How
Predicting Patient Adherence: Why and HowPredicting Patient Adherence: Why and How
Predicting Patient Adherence: Why and HowCognizant
 
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...Ruchi Vahi
 
Medication Non Adherence X
Medication Non Adherence XMedication Non Adherence X
Medication Non Adherence XDavid Donohue
 
Kumar NSGC 2015 44x44@196%-PrintReady
Kumar NSGC 2015 44x44@196%-PrintReadyKumar NSGC 2015 44x44@196%-PrintReady
Kumar NSGC 2015 44x44@196%-PrintReadyKate Lee, MPH
 
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...Health IT Conference – iHT2
 
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...Healthcare and Medical Sciences
 
MedicalResearch.com: Medical Research Exclusive Interviews March 5 2015
MedicalResearch.com:  Medical Research Exclusive Interviews March 5  2015MedicalResearch.com:  Medical Research Exclusive Interviews March 5  2015
MedicalResearch.com: Medical Research Exclusive Interviews March 5 2015Marie Benz MD FAAD
 
humanastatinarticle
humanastatinarticlehumanastatinarticle
humanastatinarticlenewtonsapple
 

Similar to Patient Treatment Choices and Confidence with Physician Conflict of Interest Disclosure (20)

How to Improve the Quality of Medical Decisions
How to Improve the Quality of Medical DecisionsHow to Improve the Quality of Medical Decisions
How to Improve the Quality of Medical Decisions
 
Frosch PROs JGIM
Frosch PROs JGIMFrosch PROs JGIM
Frosch PROs JGIM
 
An Internet questionnaire to identify Drug seeking behavior in a patient in t...
An Internet questionnaire to identify Drug seeking behavior in a patient in t...An Internet questionnaire to identify Drug seeking behavior in a patient in t...
An Internet questionnaire to identify Drug seeking behavior in a patient in t...
 
Pain Validity Test to detect drug seeking behavior
Pain Validity Test to detect drug seeking behaviorPain Validity Test to detect drug seeking behavior
Pain Validity Test to detect drug seeking behavior
 
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...
Pain Validity Test identifies drug seeking behavior. Stop opioid abuse. Prote...
 
E4P0815_PatientInterest_V6
E4P0815_PatientInterest_V6E4P0815_PatientInterest_V6
E4P0815_PatientInterest_V6
 
Clearing the Error: Patient Participation in Reducing Diagnostic Error
Clearing the Error: Patient Participation in Reducing Diagnostic ErrorClearing the Error: Patient Participation in Reducing Diagnostic Error
Clearing the Error: Patient Participation in Reducing Diagnostic Error
 
Pati ent Sati sfacti on in Electi ve Major Surgery for Benign
Pati ent Sati sfacti on in Electi ve Major Surgery for BenignPati ent Sati sfacti on in Electi ve Major Surgery for Benign
Pati ent Sati sfacti on in Electi ve Major Surgery for Benign
 
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docxRunning head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
Running head CRITIQUE QUANTITATIVE, QUALITATIVE, OR MIXED METHODS.docx
 
MedicalResearch.com: Medical Research Exclusive Interviews March 24 2015
MedicalResearch.com:  Medical Research Exclusive Interviews March 24 2015MedicalResearch.com:  Medical Research Exclusive Interviews March 24 2015
MedicalResearch.com: Medical Research Exclusive Interviews March 24 2015
 
Predicting Patient Interest and Participation in Clinical Trials
Predicting Patient Interest and Participation in Clinical TrialsPredicting Patient Interest and Participation in Clinical Trials
Predicting Patient Interest and Participation in Clinical Trials
 
Predicting Patient Adherence: Why and How
Predicting Patient Adherence: Why and HowPredicting Patient Adherence: Why and How
Predicting Patient Adherence: Why and How
 
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
 
Medication Non Adherence X
Medication Non Adherence XMedication Non Adherence X
Medication Non Adherence X
 
Evidence based medicine
Evidence based medicineEvidence based medicine
Evidence based medicine
 
Kumar NSGC 2015 44x44@196%-PrintReady
Kumar NSGC 2015 44x44@196%-PrintReadyKumar NSGC 2015 44x44@196%-PrintReady
Kumar NSGC 2015 44x44@196%-PrintReady
 
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...
iHT² Health IT Summit San Francisco – Jay Srini, Chief Strategist, SCS Ventur...
 
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...
A Study to Evaluate the Cause of Different Consultant or Hospital Visit by Pa...
 
MedicalResearch.com: Medical Research Exclusive Interviews March 5 2015
MedicalResearch.com:  Medical Research Exclusive Interviews March 5  2015MedicalResearch.com:  Medical Research Exclusive Interviews March 5  2015
MedicalResearch.com: Medical Research Exclusive Interviews March 5 2015
 
humanastatinarticle
humanastatinarticlehumanastatinarticle
humanastatinarticle
 

Patient Treatment Choices and Confidence with Physician Conflict of Interest Disclosure

  • 1. TEMPLATE DESIGN © 2008 www.PosterPresentations.com On average, participants were between “Confident” and “Very Confident” in their treatment choice. Participants were asked how confident they were with their treatment choice on a 6-point Likert scale (Not at all confident, Only slightly confident, Moderately confident, Confident, Very confident, Absolutely confident). After performing a Chi-squared test, Figure 2.1 shows no significant difference (p=.29) between the levels of disclosure when patients are asked how confident they are in their treatment choice. Basically, all the patients felt that they had made the correct decision based on the information they received. This indicates that participants were not confused by the disclosure information that they were confronted with despite the medical jargon and increased information that increased disclosure entailed. Effects of Conflict of Interest on Patient Action and Attitude Roy Spece, Andrea-Gale Okoro, Ryan Keim 1 University of Arizona, James E. Rogers College of Law, 2 University of Arizona, Honors College Introduction Several studies show that physician financial conflicts of interest (“COI”) significantly increase the likelihood that conflicted physicians will order diagnostic and treatment modalities, including invasive procedures such as surgery. Many court decisions and regulations mandate disclosure of any and all information that a reasonable patient would consider material to his medical choices. Disclosure is often suggested as a remedy in the medical and other contexts, but current literature leaves uncertain disclosure’s effects on patient attitudes and action. Some studies suggest that disclosure does not change patients’ acceptance of physician recommendations, while others claim disclosure can have perverse effects such as giving patients a false sense of security. Central to court or legislative decisions whether disclosure of COI must or should be made to patients is whether disclosure does affect patients’ decisions. If it does, then that is strong evidence that patients in fact consider COI to be material information. This study investigates how patients react when confronted with information about their physicians’ COI’s in the form of ownership interests in facilities where recommended procedures will be done. Using participants from all over the country to experience our vignettes involving physician recommendations and patient choices between drug therapy or an invasive procedure for coronary artery disease, we were able to evaluate, through survey questions and scales, exactly how patients are affected by disclosure. Especially important is our finding that disclosure does significantly increase the probability that patients’ will reject their physicians’ recommendations. . Methods Logistic Regression Model of Treatment Choice Ordinal Regression Model of Confidence in Physicians On average, participants were between “Confident” and “Very Confident” in their treatment choices. . Likelihood of Seeking a Second Opinion Discussion Acknowledgments Though there was a significant difference in likelihood of seeking a second opinion between the levels of disclosure, patients were generally leaning towards a 2nd opinion. When asked to rank “likeliness” of seeking a second opinion on a 6pt, fully anchored Likert scale (1=Very Unlikely, 6= Very Likely), participants were generally between “Somewhat Likely” and “Very Likely” (88%). Thirty- seven percent of participants who received Full Disclosure were “Very Likely” to seek a second opinion, versus 27% of those who received No Disclosure.. (X2 (10)= 25.793, p = 0.004) Federalandstatestatutes,regulations,andcommonlawopinionsgoverninformation transferfromphysicianstopatients. Thefindingsheremightinformwhetherandhowthese legalmandatesshouldbealteredorbroadened,particularlyinthecurrentlyuncertaincontext ofdisclosureoffinancialconflictsofinterest.Therearethreegeneralrulesadoptedincases andregulationsconcerningdisclosurerequiredunderthedoctrineofinformedconsent:one mustdisclosethatwhichwouldbethoughtreasonablebyphysiciansgenerally,onemust disclosewhatareasonablepatientwouldconsidermaterialtohisdecisionmaking,andwhat theparticularpatientwouldconsidermaterialtohisdecisionmaking.Applicationofthebasic doctrinallawinthosejurisdictionthatrequiredisclosureofwhatareasonablepatientwould considermaterialdepends,inwholeorpart, onanempiricalquestionastowhatreasonable personswouldconsidermaterialinspecificscenarios. Thelatterquestiondepends substantiallyonwhatinfactaffectspatients’actualdecisions. Thispaperexaminesthelatter questionby,inturn,askingwhetherpatients’decisionsareaffectedbydisclosure—atdifferent levelsofdetail—ofphysicians’financialconflictsofinterestintheformofownershipinterestsin hospitalswhererecommendedprocedureswouldtakeplace.Ourfindingsintheclinical practicecontextarethatthefactofdisclosure,butnotanincreasedlevelofdisclosure,does significantlyaffectpatients’propensitytorejectfinanciallyconflictedphysicians’ recommendations.Therefore,itlogicallyfollowsthatsuchconflictsofinterestareinfact materialtopatientdecisionmaking. Onecanarguethatsuchproofshowsthatlegalbodies shouldadoptthepatient-orienteddisclosurerule,atleastinthecontextoffinancialconflictsof interest.Othershaveobjectedthatsuchdisclosuresmightconfusepatientsorgivethema falsesenseofsecurityabouttheirdoctors’fealty. Anotherobjectionisthatsuchdisclosures areunwarrantedbecausetheywillnotaffectpatients’decisions. Thefindingsherecontradict alltheseargumentsagainstdisclosure. Ourfindingsarenotonlythatdisclosureincreases patients’propensitytorejectphysicianadvice,butalsothat,withdisclosure,patientsare confidentintheirdecisions,aremorewaryoftheirphysicians,andmorelikelytoseeksecond opinions. Subjects were given one of three different vignettes either as a high risk patient (someone who has had a heart attack previously and therefore at higher risk of having another) or a low risk patient (someone who has not previously had a heart attack). The three vignettes varied by disclosure, ranging from “No Disclosure” to “ Disclosure” to “Enhanced Disclosure”, but all ended with the same two doctor recommendations and patient choices. After reading their vignettes, participants were asked a series of questions in order to measure changes in their medical choice, opinion of the doctor’s fealty, and understanding of the situation. Participants 777 subjects, recruited online via Amazon Mechanical Turk with a $0.75 incentive, consented to participate; 34 did not complete the entire experiment and 64 were excluded for not complete the survey in a timely manner, bringing the final sample to 691 subjects. The sample was predominantly white (78%) and male (61%), with some college (35%) or a Bachelor’s degree (35%), and an average age of 28 years. Figure 1| Note: Model χ2 (2) = 11.4, p = .003. Full disclosure basically inverted treatment choice against the doctor’s recommendation. Shown in both Figure 1 and Figure 1.4, increased disclosure significantly increased the likelihood that patients would ignore the doctor’s recommendation and opt for drug therapy. Figure 1.4 This figure shows the percent change, or uptake, in respondents who chose the recommended PCI treatment across the levels of disclosure and risk Figure 6. 2x3 Factorial Design for the experiment show all possible options for participants, assigned randomly. Figure 3.1 This figure shows how respondents differed in Q27, stratified by risk and separated by disclosure level. Figure 3| Note: Model χ2 (10) = 98.102, p < .001. Understanding the Treatment Choice Despite increased information with increased disclosure, participants understood their choices across all levels. A simple visual and statistical comparison of responses to the statement "I fully understand the treatment choices presented to me by the cardiologist“ demonstrates that despite conclusions of past literature, disclosing COI does not overwhelm patients or impair their ability to make decisions. In a fully anchored 6pt- Likert scale (Strongly Disagree – Strongly Agree), participants in all levels generally fell into the “Agree” category (47%). Figure 5.1 Given a fully anchored 6pt-Likert scale (1= Strongly Disagree and 6= Strongly Agree) this figure illustrates how respondents, separated by risk and disclosure, felt they understood the information given to them. X2 (10)= 5.716, p = 0.839 Confidence in Treatment Choice Figure 2.1 This figure shows the average confidence levels of respondents, in their treatment choice, in terms of risk level and disclosure level. Thanks to Dr. Charles Okoro for medical accuracy review. Thanks to Christopher Robertson and David Yokum for research guidance. Thanks to the James E. Roger Law School and University of Arizona Honors college for financial and educational support. Future Directions Given that our findings contradict those in a few other somewhat analogous investigations, we invite others to attempt to duplicate our findings. There is also need for studies that investigate the effects of other financial conflicts of interest such as fee-for- service payment, receipt of monies or other perks from pharmaceutical companies, and HMO financial incentives (be they carrot or stick). * Figure 4.1 Subjects’ likelihood of seeking a second opinion after receiving the information on their treatment options from the doctor, separated by levels of disclosure and risk. * Which course of treatment do you want to select?”) Q21 Disclosure Drug Therapy PCI Treatment Row Total ----------------------- ----------- ----------- ----------- Full Count 146 91 237 Row % 61.60% 38.40% 34.30% Column % 38.42% 29.26% ----------------------- ----------- ----------- ----------- None Count 110 127 237 Row % 46.41% 53.59% 34.30% Column % 28.95% 40.84% ----------------------- ----------- ----------- ----------- Partial Count 124 93 217 Row % 57.14% 42.86% 31.40% Column % 32.63% 29.90% ----------------------- ----------- ----------- ----------- Column Total 380 311 691 Column % 54.99% 45.01% ========== Table: Disclosure by Q27 ========== Q27 "The cardiologist had only my interests in mind in making his recommendation." Disclosure Strongly Disagree Disagree Somewhat Disagree Somewhat Agree Agree Strongly Agree Row Total ----------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- Full Count 13 40 56 78 38 12 237 Row % 5.49% 16.88% 23.63% 32.91% 16.03% 5.06% 34.30% Column % 41.94% 43.96% 44.09% 37.50% 21.35% 21.43% ----------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- None Count 1 8 28 72 94 34 237 Row % 0.42% 3.38% 11.81% 30.38% 39.66% 14.35% 34.30% Column % 3.23% 8.79% 22.05% 34.62% 52.81% 60.71% ----------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- Partial Count 17 43 43 58 46 10 217 Row % 7.83% 19.82% 19.82% 26.73% 21.20% 4.61% 31.40% Column % 54.84% 47.25% 33.86% 27.89% 25.84% 17.86% ----------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- Column Total 31 91 127 208 178 56 691 Column % 4.49% 13.17% 18.38% 30.10% 25.76% 8.10% No Disclosure Full Disclosure Partial Disclosure High Risk Previous MI No Disclosure Previous MI Disclosure Explanation of Disclosure Previous MI Disclosure Low Risk No MI No Disclosure No MI Disclosure Explanation of Disclosure No MI Disclosure Understandingofchoices